Apoptosis
The number of cells in multicellular organism is tightly regulated. Not simply by controlling the rate of cell division, but also by controlling the rate of cell death. If cells are no longer needed, they commit suicide by activating an intracellular death program. This process is therefore called programmed cell death or apoptosis (from a Greek word meaning “falling off,” as leaves from a tree). The intrinsic apoptotic pathway occurs by the release of cytochrome c from mitochondria. The extrinsic apoptotic pathway is caused by the binding of death ligands, such as TNF (tumor necrosis factor), Fas, and TRAIL (TNF-related-apoptosis-inducing ligand), to their corresponding receptors. Although programmed cell death is involved in a number of key biological phenomena, aberrant apoptosis results in diverse human diseases [1].
The amount of apoptosis that occurs in developing and adult animal tissues is surprisingly large. In the developing vertebrate nervous system up to half or more of the nerve cells normally die soon after they are formed. In a healthy adult human, billions of cells die in the bone marrow and intestine every hour. Although this process seems remarkably wasteful -especially as the vast majority are perfectly healthy at the time they kill themselves- programmed cell death plays an important role during embryonic development, as hands and feet, for example, are sculpted by apoptosis: they start out as spadelike structures, and the individual digits separate only as the cells between them die. In other cases, cells die when the structure they form is no longer needed. When a tadpole changes into a frog, the cells in the tail die, and the tail, which is not needed in the frog, disappears. In many other cases, cell death helps regulate cell numbers. In the developing nervous system, for example, cell death adjusts the number of nerve cells to match the number of target cells that require innervation. In all these cases, the cells die by apoptosis as well[2].
[2] D.R. Williams et al. An apoptosis-inducing small molecule that binds to heat shock protein 70. Angew. Chem. Int. Ed. Engl. 2008, 47, 7466-7469.
[1] B. Alberts, A. Johnson, J. Lewis et al. Molecular Biology of the Cell. 4th edition. New York. Garland Science, 2002.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
2469 | YK 4-279 | Inhibitor of ETV1, ERG and interactions of EWS-FLI1 and RNA helicase A | €95.00 | |
3801 | Voruciclib | Inhibitor of CDK9 | Inquire | |
2100 | Trovafloxacin mesylate | Inhibitor of bacterial DNA gyrase and Topo IV | €110.00 | |
2914 | TAS-103 dihydrochloride | Dual inhibitor of topoisomerase I (Topo 1) and topoisomerase II (Topo 2) | €95.00 | |
3587 | STM2457 | First-in-class, highly potent and selective catalytic METTL3 inhibitor | €130.00 | |
1670 | STF 083010 | IRE1α inhibitor | €95.00 | |
2314 | Stattic | Nonpeptidic small-molecule inhibitor of STAT3 activation, dimerization, and nuclear translocation | €50.00 | |
2731 | STAT5 Inhibitor 1 [285986-31-4] | Nonpeptidic small-molecule inhibitor of STAT5 activation | €90.00 | |
2764 | SIS3 | Potent and selective inhibitor of Smad3 and TGF-βR1 signaling | €135.00 | |
2244 | SCH 529074 | Small molecule activator of mutant p53. | €120.00 | |
2313 | S3I 201 | Potent, cellular STAT3 inhibitor | €90.00 | |
2690 | PHA-767491 | Dual CDC7/CDK9 kinase inhibitor | €95.00 | |
2497 | Omaveloxolone | Triterpenoid activator of NRF2 and inhibitor of NF-κB | €90.00 | |
2564 | NSC 59984 | Activator of p53 that restores WT p53 signaling via p73 activation | €95.00 | |
1402 | NSC 348884 | NPM inhibitor | €120.00 | |
2016 | NSC 319726 | Reactivator of the p53 mutant p53R175 | €95.00 | |
2517 | Napabucasin | Oral first-in-class cancer stemness inhibitor that works by targeting STAT3 | €105.00 | |
3229 | MYCi975 | MYC inhibitor | €120.00 | |
2671 | ML385 | Inhibitor of NRF2 | €120.00 | |
2641 | ML334 | Activator of NRF2 by inhibition of Keap1-NRF2 interactions | €130.00 | |
3223 | MKC8866 | Potent IRE1α inhibitor | €105.00 | |
3670 | MKC-3946 | Potent and selective IRE1α inhibitor | €120.00 | |
2759 | ME0328 | PARP3/ARTD3 inhibitor | €95.00 | |
3283 | LY2857785 | Highly potent, selective, reversible and ATP-competitive CDK9 inhibitor | €180.00 | |
2242 | Levofloxacin Q-acid | Inhibitor of bacterial DNA gyrase and topoisomerase IV | €55.00 | |
3029 | LDC000067 | Potent, highly specific, ATP-competitive CDK9 inhibitor | €110.00 | |
1367 | KU-55933 | ATM inhibitor | €110.00 | |
2001 | KU-0058948 hydrochloride | Potent and specific PARP1 inhibitor | €135.00 | |
4179 | KU-0058948 | Potent and specific PARP1 inhibitor | €135.00 | |
2538 | KRIBB11 | HSF1 inhibitor that blocks the induction of HSP27 and HSP70 | €125.00 |